Links from our newsletters
You are interested in the studies we introduced in our latest newsletters?
Here we linked them for you.
"Cytokine Storm Biomakers"
Several studies investigating severe COVID-19 cases, cite a hyperactivation of the inflammatory response, leading to a cytokine release syndrom, also called cytokine storm.
Many reports show elevated levels of IL-1, IL-6 , TNF-α and C-reactive protein (CRP), additionally, a protective effect for blood type 0 is discussed.
Read more in the following studies.
Levi, M. et al. (2020) Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol. 7(6): e438–e440.
Kermali, M. et al. (2020) The role of biomarkers in diagnosis of COVID-19 – A systematic review. Life Sci 117788.
Chen, L. et al. (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Chinese J Tuberculosis Respir Dis 43(0):E005
Guan, W. et al. (2020) Clinical Characteristics of Coronavirus Disease 2019 in China. NEJM. 382: 18
Wang, W. et al. (2020) The definition and risks of Cytokine Release Syndrome-Like in 11 COVID-19-Infected Pneumonia critically ill patients: Disease Characteristics and Retrospective Analysis. medRxiv
"20 Years Immunoassay Expertise"
Chimera Biotec Celebrates!
Starting in 2000, with our proprietary Immuno-PCR platform Imperacer®, Chimera has specialized in ultra sensitive GLP/GCP bioanalytical support for all phases of drug discovery.
Get your assay! Get excellence!
♦ GLP / GCP test facility
♦ Non-regulated, preclinical & clinical support
♦ Compliant with FDA & EMA guidances
♦ Ultra sensitive immunoassay platforms
♦ Assay feasibility
♦ Full assay devevlopment services
♦ Kit-based services
Ever wondered how
companies come up
with their names?
This is our story:
A Chimera is a mixed being in Greek mythology:
“She was of divine stock, not of men, in the fore part a lion, in the hinder a serpent, and in the midst a goat, breathing forth in terrible wise the might of blazing fire.” (Homer, Iliad 6,180 ff.)
Our Chimera is the Immuno-PCR platform Imperacer®, in which antibody-DNA conjugates combine ELISA-type immunoassay setup with exponential PCR read-out:
“She was of ultra sensitivity, in the fore part antibody, in the hinder DNA, enabling forth in outstanding sensitive wise the might of groundbreaking science.”
Bring together Imperacer®, AnySource® and Chimera´s 20 years of experience in beyond ELISA sensitive immunoassays, combining ultra sensitivity, broad assay range and minimal sample volume requirement.
That´s why Chimera Biotec: We provide optimal assay development for your target and bioanalysis under GLP/GCP regulations.
"Bispecific T Cell Engager - Their Role in Immuno-Oncology"
Here, Ma et al. (2020) describe T cell engagers (TCEs) binding to the tumor marker CEA (serum carcinoembryonic antigen) on cancer cells
and CD3 on T cells in the tumor compartment to form bivalent TCE ternary complex (biTTC).
They use a quantitative systems pharmacology (QPS) model to explore TCE efficiency, identify potential biomarkers
and can even predict patient-specific response to TCE treatment.
We routinely develop and validate ultra sensitive PK assays for GLP/GCP regulated bioanalytical sample testing support of bispecific antibody-based therapies, such as TCRs, for treatment of various malignancies.
Chimera´s AnySource® sample dilution minimizes matrix effects, enabling therapeutic antibodies target detection in the presence of ~ 1,000,000-fold excess of endogenous antibodies.
We offer complete service packages (PK/PD, Immunogenicity, Biomarker) across multiple platforms.
"Neurodegenerative Diseases - Bioanalytical Solutions"
Here, Yoo et al. (2020) suggest soluble Aβ*56 and AβO as potential biomarkers for AD in nasal discharge.
While increased levels in Aβ*56 alone can indicate mild AD, additionally increased AβO levels give hint to a moderate stage.
This suggests soluble Aβ*56 and AβO as potential biomarkers for AD in nasal discharge.
To address the low oral bioavailability and side effects of levodopa, Arisoy et al. (2020) used nano-sized drug carriers for nose to brain delivery.
The levodopa-coated biocompatible nanoparticles prolonged release up to 9h and improved locomotor activity in Parkinson´s Diesease model in mice.
Please feel free to contact Chimera Biotec’s team of dedicated scientists for more in-depth information. We are looking forward to provide you with the immunoassay to exceed your highest expectations.